These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2571386)

  • 81. Cutaneous vasculitis and IgA glomerulonephritis in ankylosing spondylitis.
    Beauvais C; Kaplan G; Mougenot B; Michel C; Marinho E
    Ann Rheum Dis; 1993 Jan; 52(1):61-2. PubMed ID: 8427517
    [TBL] [Abstract][Full Text] [Related]  

  • 82. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study.
    Taggart A; Gardiner P; McEvoy F; Hopkins R; Bird H
    Arthritis Rheum; 1996 Aug; 39(8):1400-5. PubMed ID: 8702450
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
    van Denderen JC; van der Paardt M; Nurmohamed MT; de Ryck YM; Dijkmans BA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2005 Dec; 64(12):1761-4. PubMed ID: 15901634
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Should tests for proteinuria be included in the monitoring schedule of sulphasalazine?
    Helliwell PS
    Br J Rheumatol; 1995 Aug; 34(8):790-1. PubMed ID: 7551669
    [TBL] [Abstract][Full Text] [Related]  

  • 86. IgA-nephropathia in a patient with ankylosing spondylitis.
    Andersen GN
    Scand J Rheumatol; 1992; 21(1):46-7. PubMed ID: 1570488
    [No Abstract]   [Full Text] [Related]  

  • 87. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews.
    Andreasen RA; Kristensen LE; Baraliakos X; Strand V; Mease PJ; de Wit M; Ellingsen T; Hansen IMJ; Kirkham J; Wells GA; Tugwell P; Maxwell L; Boers M; Egstrup K; Christensen R
    Arthritis Res Ther; 2020 Jul; 22(1):177. PubMed ID: 32711571
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis.
    Nossent JC; Sagen-Johnsen S; Bakland G
    Rheumatol Ther; 2019 Sep; 6(3):369-378. PubMed ID: 31147969
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Oral Anaerobic Bacteria in the Etiology of Ankylosing Spondylitis.
    Öğrendik M
    Clin Med Insights Arthritis Musculoskelet Disord; 2017; 10():1179544117712992. PubMed ID: 28638241
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Periodontal Pathogens are Likely to be Responsible for the Development of Ankylosing Spondylitis.
    Ogrendik M
    Curr Rheumatol Rev; 2015; 11(1):47-49. PubMed ID: 26002454
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study.
    Relas H; Kautiainen H; Puolakka K; Virta LJ; Leirisalo-Repo M
    Clin Rheumatol; 2014 Aug; 33(8):1135-8. PubMed ID: 24907035
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial.
    Song IH; Hermann K; Haibel H; Althoff CE; Listing J; Burmester G; Krause A; Bohl-Bühler M; Freundlich B; Rudwaleit M; Sieper J
    Ann Rheum Dis; 2011 Apr; 70(4):590-6. PubMed ID: 21372193
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.
    Stoll ML
    Clin Exp Rheumatol; 2011; 29(2):322-30. PubMed ID: 21269576
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis.
    Chang X; Han J; Zhao Y; Yan X; Sun S; Cui Y
    BMC Musculoskelet Disord; 2010 Dec; 11():279. PubMed ID: 21143847
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.
    Goh L; Samanta A
    Rheumatol Int; 2009 Aug; 29(10):1123-35. PubMed ID: 19562344
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pharmacological treatment of ankylosing spondylitis: a systematic review.
    Boulos P; Dougados M; Macleod SM; Hunsche E
    Drugs; 2005; 65(15):2111-27. PubMed ID: 16225367
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Current guidelines for the drug treatment of ankylosing spondylitis.
    Toussirot E; Wendling D
    Drugs; 1998 Aug; 56(2):225-40. PubMed ID: 9711447
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Does methotrexate affect serum level of IgA-alpha-1 antitrypsin complex in early rheumatoid arthritis?
    Lacki JK; Schochat T; Klama K; Mackiewicz SH; Müller W
    Clin Rheumatol; 1995 Sep; 14(5):566-9. PubMed ID: 8549097
    [No Abstract]   [Full Text] [Related]  

  • 99. Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis.
    Kanerud L; Engström GN; Tarkowski A
    Ann Rheum Dis; 1995 Apr; 54(4):256-62. PubMed ID: 7763101
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.